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Abstract
Among several commonly used atypical antipsychotic drugs, olanzapine and risperidone cause a
sensitization effect in the conditioned avoidance response (CAR) and phencyclidine (PCP)-
induced hyperlocomotion paradigms – two well established animal tests of antipsychotic drugs,
whereas clozapine causes a tolerance effect. Asenapine is a novel antipsychotic drug recently
approved for the treatment of schizophrenia and manic disorders. It shares several receptor
binding sites and behavioral features with other atypical antipsychotic drugs. However, it is not
clear what type of repeated effect (sensitization or tolerance) asenapine would induce, and whether
such an effect is transferrable to other atypicals. In this study, male adult Sprague-Dawley rats
were first repeatedly tested with asenapine (0.05, 0.10 or 0.20 mg/kg, sc) for avoidance response
or PCP (3.20 mg/kg, sc)-induced hyperlocomotion daily for 5 consecutive days. After 2–3 days of
retraining/drug-free recovery, they were then challenged with asenapine (0.10 mg/kg, sc),
followed by olanzapine (0.50 mg/kg, sc) and clozapine (2.50 mg/kg, sc). During the 5-day drug
test period (the induction phase), repeated asenapine treatment progressively increased its
inhibition of avoidance response and PCP-induced hyperlocomotion in a dose-dependent fashion.
On the asenapine and olanzapine challenge tests (the expression phase), rats previously treated
with asenapine still showed significantly lower avoidance response and lower PCP-induced
hyperlocomotion than those previously treated with vehicle. An increased reactivity to clozapine
challenge in prior asenapine-treated rats was also found in the PCP-induced hyperlocomotion test.
These findings suggest that asenapine is capable of inducing a sensitization effect and a cross-
sensitization to olanzapine and clozapine (to a lesser extent). Because the behavioral profile of
asenapine in both tests is similar to that of olanzapine, but different from that of clozapine, we
suggest that asenapine resembles olanzapine to a greater extent than clozapine in its therapeutic
and side effect profiles.
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1. Introduction
Asenapine (US brand name: Saphris; EU brand name: Sycrest) is a new atypical
antipsychotic medication recently approved for the acute and maintenance treatment of
schizophrenia and treatment of acute manic or mixed episodes associated with bipolar I
disorder (Tarazi and Neill, 2012; Tarazi and Shahid, 2009). It has a multiple receptor
binding profile similar to those of other atypical antipsychotic drugs (e.g. clozapine,
olanzapine), with higher antagonist action against serotonin receptors (5-HT2A, 5-HT2C, 5-
HT6, 5-HT7), adrenergic α1 and α2 receptors, histamine H1 and H2 receptors, and a
relatively lower action on dopamine D2 and D1 receptors (Shahid et al., 2009). Clinical
studies suggest that it is well tolerated and does not cause severe weight gains (Howland,
2011; Meltzer et al., 2009). Preclinical studies suggest that asenapine can dose-dependently
enhance dopamine and acetylcholine release in the medial prefrontal cortex and
hippocampus (Franberg et al., 2012; Huang et al., 2008), and may even possess a
procognitive property (Elsworth et al., 2012; McLean et al., 2010; Snigdha et al., 2011).
In recent years, we have systematically investigated the repeated effects of antipsychotic
treatment using preclinical tests of antipsychotic activity (Li et al., 2007, 2010; Sun et al.,
2009). We have identified two behavioral patterns (sensitization and tolerance) commonly
associated with chronic use of drugs of abuse in two independent paradigms of antipsychotic
activity: the conditioned avoidance response (CAR) and phencyclidine (PCP)-induced
hyperlocomotion (Feng et al., 2013; Li et al., 2012; Mead and Li, 2010; Qiao et al., 2013;
Swalve and Li, 2012; Zhang and Li, 2012). Specifically, we show that repeated
administration of haloperidol, olanzapine or risperidone daily for 5–7 days tends to cause a
progressively increased inhibition of avoidance responding and PCP-induced
hyperlocomotion (a sensitization effect). When rats are given a challenge dose of these
drugs at a later point, they also exhibit a sensitization effect as they often make significantly
fewer avoidance responses and exhibit lower PCP-induced hyperlocomotion than those that
are treated with these drugs for the first time (Li et al., 2009a, b; Li et al., 2010; Mead and
Li, 2010; Qiao et al., 2013; Sun et al., 2009; Zhao et al., 2012). In addition, we show that
haloperidol-induced sensitization is transferable to olanzapine-induced sensitization and vice
versa, an intriguing finding that may be useful in determining the similarities or differences
of different antipsychotic drugs (Li et al., 2007; Mead and Li, 2010).
Clozapine is the only tested antipsychotic that displays a different behavioral pattern in these
tests. During the daily drug test phase, repeated administration of clozapine causes no
apparent sensitization or tolerance (Li et al., 2010; Qiao et al., 2013; Sun et al., 2009). But
on the challenge test, a tolerance effect is often observed as rats previously treated with
clozapine make significantly more avoidance responses and exhibit higher PCP-induced
hyperlocomotion than those that are treated with clozapine for the first time (Feng et al.,
2013; Li et al., 2010; Qiao et al., 2013). The exact nature of clozapine tolerance and its
clinical relevance are not entire clear; it could be connected to its unique clinical profile (e.g.
superior therapeutic efficacy and little extrapyramidal side effects) in some way (Meltzer,
2012).
Given the fact that an atypical antipsychotic drug exhibits either a sensitization or tolerance
behavioral patterns in the CAR and PCP-induced hyperlocomotion tests, which may reveal
their clinical properties and receptor mechanisms, to better understand the preclinical profile
of asenapine, it is important to determine what type of repeated effect (sensitization or
tolerance) asenapine would induce, and whether such an effect is transferable to other
atypical antipsychotic drugs. Furthermore, only one study examined the acute effect of
asenapine in the CAR (Franberg et al., 2008), and there is no reported study on its efficacy
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in the PCP-induced hyperlocomotion test. The present study was also designed to address
this deficiency.
2. Materials and methods
2.1. Animals
All experimental treatment and procedures were approved by the Institutional Animal Care
and Use Committee at the University of Nebraska-Lincoln. Adult male Sprague-Dawley rats
(226–250 g or 276–300 g upon arrival, Charles River, Portage, MI) were housed two per
cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages under 12-h light/dark
conditions (light on between 6:30 am and 6:30 pm). Room temperature was maintained at 22
± 1 °C with a relative humidity of 45–60%. Food and water was available ad libitum.
Animals were allowed at least 5 days of habituation to the animal facility before being used
in experiments. All behavioral tests took place between 9 am and 5 pm in the light cycle.
2.2. Drugs and choice of doses
Asenapine Maleate (a gift from the NIMH drug supply program) was dissolved in 0.9%
saline. Doses of asenapine (0.05, 0.10 and 0.20 mg/kg) were determined based on previous
studies showing that this dose range of asenapine causes a dose-dependent suppression of
CAR but does not cause severe motor impairment (Franberg et al., 2008; Marston et al.,
2009) and is effective to cause an increase of dopamine, acetylcholine and norepinephrine
efflux in the medial prefrontal cortex and hippocampus (Huang et al., 2008). Both
olanzapine (OLZ, 0.50 mg/kg) and clozapine (CLZ, 2.50 mg/kg) (gifts from the NIMH drug
supply program) were dissolved in distilled sterile water with 1.0–1.5% glacial acetic acid.
Phencyclidine hydrochloride (PCP, gift from the NIDA Chemical Synthesis and Drug
Supply Program) was dissolved in 0.9% saline. The dose of PCP (3.20 mg/kg) was chosen
based on our previous work (Sun et al., 2009, 2010; Zhang and Li, 2012; Zhao et al., 2012).
This dose of PCP is shown to induce a robust hyperlocomotion effect without causing severe
stereotypy (Gleason and Shannon, 1997; Kalinichev et al., 2008). All drugs were
administrated subcutaneously (sc) at 1.0 ml/kg.
2.3. Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med
Associates (St. Albans, VT) were used. Each box was housed in a ventilated, sound-
insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm
long, 30 cm high (from grid floor), and 24 cm wide, and was divided into two equal-sized
compartments by a partition with an arch style doorway (15 cm high × 9 cm wide at base). A
barrier (4 cm high) was placed between the two compartments, so the rats had to jump from
one compartment to the other. The grid floor consisted of 40 stainless-steel rods with a
diameter of 0.48 cm, spaced 1.6 cm apart center to center, through which a scrambled
footshock (US, 0.8 mA, maximum duration: 5 s) was delivered by a constant current shock
generator (Model ENV-410B) and scrambler (Model ENV-412). The rat location and
crossings between compartments were monitored by a set of 16 photobeams (ENV-256-8P)
affixed at the bottom of the box (3.5 cm above the grid floor). Illumination was provided by
two houselights mounted at the top of each compartment. The CS (i.e. 76 dB white noise)
was produced by a speaker (ENV 224 AMX) mounted on the ceiling of the cubicle, centered
above the shuttle box. Background noise (approximately 74 dB) was provided by a
ventilation fan affixed at the top corner of each isolation cubicle. All training and testing
procedures were controlled by Med Associates programs running on a computer.
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2.4. Locomotor activity monitoring apparatus
This apparatus has been described before (Feng et al., 2013; Sun et al., 2009; Zhao and Li,
2012). Sixteen activity boxes were housed in a quiet room. The boxes were 48.3 cm × 26.7
cm × 20.3 cm transparent polycarbonate cages, which were similar to the home cages but
were each equipped with a row of 6 photocell beams (7.8 cm between two adjacent
photobeams) placed 3.2 cm above the floor of the cage. A computer with recording software
(Aero Apparatus Sixbeam Locomotor System v1.4, Toronto, Canada) was used to detect the
disruption of the photocell beams and record the number of beam breaks. All experiments
were run during the light cycle.
2.5. Experiment 1: effects of repeated asenapine treatment on avoidance response
This experiment examined whether repeated asenapine treatment induces a sensitization or
tolerance effect in the CAR model and whether prior asenapine treatment would alter the
avoidance-disruptive effect of olanzapine and clozapine (i.e. cross-sensitization or
tolerance). The experiment was comprised of the following three phases: Phase 1:
Avoidance training and 5 days of repeated asenapine testing; Phase 2: Asenapine challenge
test; and Phase 3: Olanzapine and clozapine challenge tests.
2.5.1. Phase 1: avoidance training in CAR and 5 days of repeated asenapine
testing—Forty rats were first habituated to the CAR boxes for 2 days (30 min/day). They
were then trained for conditioned avoidance responding for 10 days/sessions. Each session
consisted of 30 trials, and each trial started by presenting a white noise (CS) for 10 s,
followed by a continuous scrambled footshock (0.8 mA, US, maximum duration = 5 s) on
the grid floor. An avoidance response was recorded if a subject moved from one
compartment into the other within the 10 s of CS presentation. An escape response was
recorded if the rat remained in the same compartment for more than 10 s and made a
crossing upon receiving the footshock. If the rat did not respond during the entire 5 s
presentation of the shock, the trial was terminated and the intertrial intervals started. The
total number of avoidance responses was recorded for each session. Inter-trial intervals
varied randomly between 30 and 60 s.
At the end of the training session, 35 rats reached the training criterion (≥70% avoidance in
each of the last 2 sessions). They were first matched on avoidance performance on the last
training day (i.e. pre-drug) to create blocks of rats (n = 4 rats/block) that were approximately
equal in performance. Within each block, they were then randomly assigned to 1 of 4
groups: asenapine 0.05 mg/kg (ASE 0.05, n = 9), asenapine 0.10 mg/kg (ASE 0.10, n = 8),
asenapine 0.20 mg/kg (ASE 0.20, n = 9) and vehicle (VEH, n = 9), and tested daily under
the CS-only (no shock, 30 trials/session) condition for 5 consecutive days, following the
same procedure as employed before (Feng et al., 2012, 2013; Swalve and Li, 2012; Zhang
and Li, 2012). On each test day, rats were first injected with asenapine or saline; 30 min
later, they were placed in the CAR boxes and tested.
2.5.2. Phase 2: asenapine challenge test—One day after the last (5th) asenapine test
day, all rats were retrained drug-free for 1 session under the CS-only (no shock) condition,
followed by another under the CS–US condition to bring their avoidance responses back to
the pre-drug level. These 2 retraining sessions also ensured that all groups had a comparable
level of avoidance responding before the asenapine challenge test, which occurred 1 day
after the 2nd retraining session. On the challenge day, all rats were injected with asenapine
at 0.10 mg/kg and tested for avoidance performance, in the CS-only condition (30 trials) 30
min later.
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2.5.3. Phase 3: olanzapine and clozapine challenge tests—Two days after the
asenapine challenge test, all rats were once again retrained for 2 sessions (1 under the CS-
only and 1 under the CS–US condition), followed by the olanzapine challenge test 1 day
later. Similar to the asenapine challenge test, all rats were injected with olanzapine 0.50 mg/
kg and tested for avoidance performance, in the CS-only condition (30 trials) 1 h later. This
challenge procedure has been successfully used in our previous studies (Li et al., 2012,
2010; Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li, 2012). Two days later,
all rats were retrained and challenged under clozapine (2.50 mg/kg, sc). The basic procedure
was identical to that of olanzapine. Fig. 1 summarizes the entire experimental procedure and
groups at different phases of the experiment.
2.6. Experiment 2: effects of repeated asenapine treatment on the PCP-induced
hyperlocomotion
This experiment examined how repeated asenapine (0.05, 0.10, 0.20 mg/kg, sc) treatment
affects the PCP-induced hyperlocomotion. It was designed to examine the generality of
asenapine sensitization across different tests of antipsychotic activity. The entire experiment
was comprised of the following three phases: Phase 1: Five days of repeated asenapine
testing; Phase 2: Asenapine challenge test; and Phase 3: Olanzapine and clozapine
challenge tests.
2.6.1. Phase 1: five days of repeated asenapine testing—Forty-eight rats were
randomly assigned to 1 of 5 groups: VEH + VEH (saline + saline, n = 16), VEH + PCP
(saline + PCP 3.20 mg/kg, n = 8); ASE 0.05 + PCP (ASE 0.05 mg/kg + PCP 3.20 mg/kg, n
= 8), ASE 0.1 + PCP (ASE 0.10 mg/kg + PCP 3.20 mg/kg, n = 8) and ASE 0.2 + PCP (ASE
0.20 mg/kg + PCP 3.20 mg/kg, n = 8). All rats were first handled and habituated to the
locomotor activity apparatus for 2 days (30 min/day). On each of the next 5 consecutive
days, they were first injected with vehicle (saline), ASE 0.05, 0.10, or 0.20 mg/kg and then
immediately placed in the boxes for 30 min. At the end of the 30-min period, they were
taken out and injected with vehicle (saline) or PCP (3.20 mg/kg, sc) and placed back in the
boxes for another 60 min. Locomotor activity (number of photebeam breaks) was measured
in 5 min intervals throughout the entire 90-min testing session.
2.6.2. Phase 2: asenapine challenge test—Two days after the last (5th) ASE test, all
rats were returned to the locomotor activity boxes for 1 re-habituation session (30 min),
followed by the asenapine challenge test 1 day later. On the challenge day, the VEH + VEH
group was split into two subgroups (n = 8/subgroup): the VEH + VEH-1 group and VEH +
VEH-2 group. All rats were first injected with asenapine 0.10 mg/kg and then immediately
placed in the locomotor activity boxes for 30 min. At the end of the 30-min period, they
were taken out and injected with either saline (VEH + VEH-1, n = 8) or PCP (3.20 mg/kg)
(VEH + VEH-2 and other rats) and placed back in the boxes for another 60 min.
2.6.3. Phase 3: olanzapine and clozapine challenge tests—Three days after the
last asenapine challenge test, all rats were returned to the locomotor activity boxes for 1 re-
habituation session (30 min), followed by the olanzapine challenge test 1 day later. On the
challenge test day, all rats were first injected with olanzapine 0.50 mg/kg and then
immediately placed in the motor activity boxes for 30 min. At the end of the 30-min period,
rats were taken out and injected with saline (VEH + VEH-1) or PCP (3.20 mg/kg), and
placed back in the boxes for another 60 min.
The basic procedure of clozapine challenge test was identical to that of olanzapine. The dose
of clozapine administration was 2.50 mg/kg Fig. 2 summarizes the experimental procedure
and groups at different phases of the experiment.
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2.7. Statistical analysis
All data were expressed as mean + SEM. Data from the 5 drug test sessions (e.g. avoidance
response and PCP-induced hyperlocomotion) were analyzed using a factorial repeated
measures analysis of variance (ANOVA) with the between-subjects factor being drug group
and the within-subjects factor being test session, followed by post hoc LSD tests.
Differences between groups on the specific drug test days and on the challenge tests were
analyzed using one-way ANOVAs, followed by post hoc LSD tests. For all analyses, p ≤
0.05 was considered statistically significant and all data were analyzed using SPSS version
19.
3. Results
3.1. Experiment 1: effects of repeated asenapine treatment on avoidance response
3.1.1. Phase 1: five days of repeated asenapine testing—Fig. 3 shows the mean
number of avoidance responses made by rats in the four groups on the last training (pre-
drug) day and 5 drug test days. There was no group difference on the last training day (pre-
drug). Throughout the 5 drug test days, asenapine increased its suppression of avoidance
response progressively in a dose-dependent way. Two-way repeated measures ANOVA
revealed a main effect of group, F(3, 31) = 42.445, p < 0.001; day, F(4, 124) = 42.061, p <
0.001 and a significant group × day interaction, F(12,124) = 5.603, p < 0.001. Post hoc LSD
tests show that all three asenapine groups made significantly fewer avoidance responses than
the VEH group, all ps ≤ 0.001; and the ASE 0.10 and ASE 0.20 groups also had
significantly lower avoidance than that of the ASE 0.05 group, all ps < 0.001. The difference
between the ASE 0.10 and ASE 0.20 group was marginally significant, p = 0.05. One-way
ANOVAs on each test day revealed that the ASE 0.10 and ASE 0.20 groups had
significantly lower avoidance than the VEH group and the ASE 0.05 group on all 5 days, ps
< 0.005, while the ASE 0.05 group showed significantly lower avoidance than the VEH
group on last three drug test days, ps < 0.001.
3.1.2. Phase 2: asenapine challenge test—Fig. 4A shows the number of avoidance
responses on the pre-drug day and the asenapine challenge day. No significant group
difference was detected on the pre-drug day. On the challenge day when all rats were
injected with asenapine 0.10 mg/kg, the three ASE groups made fewer avoidance responses
than the VEH group. One-way ANOVA confirmed a main effect of group, F(3, 31) = 6.047,
p = 0.002. Post hoc LSD tests showed that the ASE 0.10 and ASE 0.20 groups were
significantly different from the VEH group, p = 0.003 and 0.001, respectively, and the ASE
0.20 group was also significantly different from the ASE 0.05 group, p = 0.027.
3.1.3. Phase 3: olanzapine and clozapine challenge tests—Fig. 4B shows the
number of avoidance responses on the pre-drug day and the olanzapine challenge test day.
Before the OLZ challenge, there was no significant group difference. On the challenge day
when all rats were injected with OLZ 0.50 mg/kg, the three ASE groups once again made
fewer avoidance responses than the VEH group, indicating a cross sensitization to
olanzapine. One-way ANOVA showed a significant effect of group, F(3, 31) = 4.645, p =
0.009. Post hoc LSD tests showed that the ASE 0.05, ASE 0.10 and ASE 0.20 groups were
significantly different from the VEH group, p = 0.043, 0.001 and 0.034, respectively. For the
clozapine challenge (Fig. 4C), although no significant group difference on the pre-drug day
and on the CLZ (2.50 mg/kg) challenge day was found, ps > 0.522, the two ASE groups
(0.10 and 0.20 mg/kg) did exhibit non-significantly lower avoidance than the VEH group.
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Collectively, results from this experiment suggest that repeated asenapine treatment induced
a sensitization and a cross-sensitization effect to olanzapine in conditioned avoidance
response model. But there is no cross-sensitization to clozapine.
3.2. Experiment 2: effects of repeated asenapine treatment on the PCP-induced
hyperlocomotion
3.2.1. Phase 1: five days of repeated asenapine testing—Fig. 5A shows the mean
locomotor activity of the rats of five groups during the 60-min test period after vehicle or
PCP injection throughout the 5 days of drug testing. Two-way repeated measures ANOVA
revealed a significant main effect of group, F(4, 43) = 70.443, p < 0.001; day, F(4, 172) =
6.013, p < 0.001 and a significant group × day interaction, F(16, 172) = 2.389, p = 0.003.
Post hoc LSD tests revealed that the VEH + PCP group was significantly different from the
VEH + VEH group, p < 0.001, indicating a strong psychomotor activation effect of this dose
of PCP. The low ASE (0.05 mg/kg) group had significantly higher locomotor activity,
whereas the high ASE (0.20 mg/kg) group had significantly lower motor activity than the
VEH + PCP group, all ps < 0.001. In addition, the three ASE groups differed significantly
from each other, all ps < 0.001. These findings imply a dose-dependent inhibition of the
PCP-induced hyperlocomotion. This inhibition was not complete, as the three ASE groups
still differed significantly from the VEH + VEH group, all ps ≤ 0.002.
To identify the behavioral patterns of the effects of repeated drug treatment (e.g. ASE and
PCP) on the motor activity throughout the 5 drug test days, we compared activity data in 5-
min blocks on day 1 with those on day 5 for each drug group (Fig. 5B–F). Two-way
repeated measures ANOVA on the 5-min block data revealed a main effect of block, F(11,
154) = 11.318, p < 0.001, and block × day interaction, F(11, 154) = 6.845, p < 0.001, but no
main effect of day, F(1, 14) = 0.813, p = 0.382 in the VEH + PCP group. The main effect of
block and block × day interaction were also significant in the ASE 0.05 + PCP group, all ps
< 0.001. For the ASE 0.20 + PCP group, the main effects of block, day, and block × day
interaction were all significant, all ps < 0.001, suggesting that repeated asenapine treatment
progressively strengthened its inhibition of PCP-induced hyperlocomotion.
3.2.2. Three re-habituation sessions—On the 1st, 2nd and 3rd re-habituation days
before the asenapine, olanzapine and clozapine challenge tests, all rats were placed in the
locomotor activity boxes for 30 min with no drug treatment, and one-way ANOVA did not
find any significant group difference, all ps > 0.066 (data not shown).
3.2.3. Phase 2 and 3: asenapine, olanzapine and clozapine challenge tests—
Fig. 6A shows the mean locomotor activity during the 60-min test period after the vehicle or
PCP injection on the asenapine challenge test. First, an independent samples t test found that
the VEH + VEH-2 group (treated with PCP) had significantly higher locomotor activity than
the VEH + VEH-1 group (treated with saline), t(14) = −5.108, p = 0.001. A one-way
ANOVA on the PCP-treated groups (5 groups excluding the VEH + VEH-1 group) found a
main effect of group, F(4, 35) = 3.358, p = 0.02. Post hoc tests showed that the ASE 0.20 +
PCP group were significantly different from the VEH + VEH-2, VEH + PCP and ASE 0.05
+ PCP groups, all ps < 0.038, suggesting that prior asenapine treatment at 0.20 mg/kg
enhanced its inhibition of the PCP-induced hyperlocomotion.
Fig. 6B shows the mean locomotor activity during the 60-min test period after the vehicle or
PCP injection on the olanzapine challenge test day. An independent samples t test found that
the VEH + VEH-2 group had significantly higher motor activity than the VEH + VEH-1
group, t(14) = −11.149, p < 0.001. A one-way ANOVA on the PCP-treated groups found a
main effect of group, F(4, 35) = 6.525, p < 0.001. Post hoc LSD tests showed that the ASE
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0.10 + PCP group and ASE 0.20 + PCP group had a significantly lower locomotor activity
than the VEH + VEH-2 group, all ps ≤ 0.001, and the VEH + PCP group, p = 0.048 and p =
0.004, respectively. The ASE 0.20 + PCP group also had significantly lower locomotor
activity than the ASE 0.05 + PCP group, p = 0.012. These results suggest that repeated
asenapine treatment caused a cross-sensitization to olanzapine, a finding similar to what was
observed in the CAR model.
Fig. 6C shows the mean locomotor activity during the 60-min test period after the vehicle or
PCP injection on the clozapine challenge test day. Once again, the VEH + VEH-2 group had
significantly higher locomotor activity than the VEH + VEH-1 group, t(14) = −11.849, p <
0.001. One way ANOVA on the PCP-treated groups revealed a main effect of group, F(4,
35) = 10.968, p < 0.001. Post hoc LSD tests showed that the ASE 0.10 + PCP group and
ASE 0.20 + PCP group had significantly lower locomotor activity than the VEH + VEH-2
group, all ps < 0.001 and the VEH + PCP group, all ps < 0.016, indicating that prior
asenapine treatment increased behavioral sensitivity to clozapine. The ASE 0.20 + PCP
group also had significantly lower locomotor activity than the ASE 0.05 + PCP group, p =
0.001.
Collectively, results from this experiment suggest that repeated asenapine treatment induced
a sensitization effect and a cross-sensitization effect to both olanzapine and clozapine in the
PCP-induced hyperlocomotion model.
4. Discussion
Unlike the majority of behavioral studies of asenapine, which typically focus on its acute
efficacy, the present study examined the impact of repeated asenapine treatment on the
behavioral responsiveness to asenapine, olanzapine and clozapine. We addressed two
questions: (1) what kind of repeated effect (sensitization or tolerance) would asenapine
induce? (2) is asenapine-induced sensitization effect transferrable to other atypicals such as
olanzapine and clozapine? Using the two independent behavioral tests of antipsychotic
activity, we demonstrated that repeated asenapine treatment induced a sensitization effect in
its disruption of avoidance response and inhibition of PCP-induced hyperlocomotion. This
effect was observed during the repeated drug test period (the induction phase) and in the
challenge test (the expression phase). Furthermore, prior asenapine treatment also increased
sensitivity to olanzapine treatment in both tests and to clozapine in the PCP-induced
hyperlocomotion test. These findings reveal that similar to haloperidol, olanzapine and
risperidone, but unlike clozapine, asenapine is an antipsychotic drug capable of inducing a
long-lasting increased sensitivity to antipsychotic treatment in the CAR and PCP tests.
Because of its sensitization profile and its ability to generate a cross-sensitization to
olanzapine, asenapine may share a similar therapeutic and side effect profile with
olanzapine, rather with clozapine, despite the fact that it shares many receptor binding
profiles with clozapine (Meltzer et al., 2009; Shahid et al., 2009).
Previous work on the avoidance-disruptive effect of asenapine reports that acute asenapine
at 0.10 and 0.20 mg/kg, but not at 0.05 mg/kg, produces a significant suppression of CAR at
both 20 and 90 min after administration (Franberg et al., 2008). Our results are consistent
with this finding, as we showed that on the 1st day of drug testing, only the 0.1 and 0.2 mg/
kg asenapine, but not 0.05 mg/kg significantly disrupted avoidance response at 30–60 min
(the test lasted about 30 min) after administration. However, with repeated drug
administration and avoidance testing, 0.05 mg/kg asenapine started to significantly suppress
avoidance response on the 3rd day and maintained its suppression throughout the remaining
days. This finding clearly suggests that repeated drug exposure could alter drug sensitivity.
This point is even more conspicuous when we inspect the avoidance response data on the
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asenapine challenge test. On the pre-drug test, all 4 groups of rats (vehicle and 3 asenapine
treatment groups) had a comparably high level of avoidance responding. However, on the
challenge test, only those who had been exposed to asenapine at 0.10 and 0.20 mg/kg
showed significantly lower avoidance than the other groups. The reason that the cross-
sensitization to olanzapine did not show a dose-dependence is not clear (see Fig. 4B). Prior
asenapine challenge test and/or specific experimental parameters (e.g. olanzapine challenge
dose, number of test trials, etc.) may have made this effect less detectable. Of note, the
asenapine-induced sensitization in the avoidance test is similar to the sensitization induced
by many other antipsychotic drugs tested so far (Li et al., 2012, 2010; Mead and Li, 2010;
Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li, 2012), but different from that
of clozapine, which tends to induce a tolerance effect (i.e. prior clozapine exposure
decreases its ability to suppress avoidance response) (Feng et al., 2013; Li et al., 2012, 2010;
Qiao et al., 2013).
In the present study, we also examined the acute and repeated effects of asenapine treatment
on the PCP-induced hyperlocomotion, which, to our knowledge, has not been explored
before. Upon acute administration, most antipsychotic drugs inhibit acute PCP-induced
hyperlocomotion (Arnt, 1995; Gleason and Shannon, 1997), a feature often used to
determine the potential antipsychotic activity. Our previous work suggests that the PCP-
induced hyperlocomotion test using a repeated drug administration regimen is better in
detecting antipsychotic action, capturing the time course of the antipsychotic effect and
differentiating antipsychotics from anxiolytics (Sun et al., 2009; Zhao et al., 2012). Recent
work suggests that it is also useful in detecting antipsychotic-induced sensitization and
tolerance, as prior treatment of haloperidol and olanzapine often causes an increased
responsiveness to these drugs so that their inhibition of PCP-induced hyperlocomotion
becomes stronger, whereas prior treatment of clozapine causes a decreased responsiveness
to clozapine re-exposure so that its inhibition becomes weaker (Feng et al., 2013; Qiao et al.,
2013; Zhang and Li, 2012). Our finding that asenapine caused a sensitization effect in this
model not only supports the usefulness of this paradigm in the study of the long-term
antipsychotic treatment effect, regardless of any particular class of drugs; but also reveals
the generality of asenapine sensitization, independent of any particular behavioral test
(avoidance and motor activity). Furthermore, the cross-sensitization to olanzapine supports
the notion that asenapine possesses an olanzapine-like therapeutic profile insofar as the
inhibition of PCP-induced hyperlocomotion reflects this property.
One surprising finding was that asenapine at a low dose (i.e. 0.05 mg/kg) actually increased
the PCP-induced hyperlocomotion, an effect opposite to those of 0.10 and 0.20 mg/kg
asenapine. Other asenapine studies have also suggested that low doses of asenapine have
different behavioral effects than high doses. For example, Marston et al. (2009) found that
asenapine at high doses (>0.10 mg/kg) failed to improve performance in delayed non-match
to place (DNMTP) and five-choice serial reaction (5-CSR) tasks – cognitive tasks designed
to assess effects on short-term spatial memory and attention. At 0.30 mg/kg, it even
impaired 5-CSR accuracy. In contrast, asenapine at low doses (<0.075 mg/kg) is shown to
improve various cognitive deficits (e.g. reversal learning, cognitive flexibility, object
recognition, etc.) induced by PCP (acute or subchronic) treatment or brain lesions (McLean
et al., 2010; Snigdha et al., 2011; Tait et al., 2009). Therefore, it is possible that asenapine at
low doses exhibits a procognitive effect while at high doses it exhibits an antipsychotic
effect. At even higher doses (>0.50 mg/kg), asenapine causes catalepsy and sedation
(Franberg et al., 2008). Furthermore, because several antidepressants are known to increase
the PCP-induced hyperlocomotion (Redmond et al., 1999), it is possible that low doses of
asenapine may even possess an antidepressant property. This dose-dependent behavioral
feature of asenapine has apparent implications for clinical practice. For example, if the
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negative symptoms and cognitive deficits are the primary targets, a lower dose of asenapine
may be preferred.
At the behavioral level, the finding that repeated asenapine treatment progressively
increased its disruption of avoidance response and PCP-induced hyperlocomotion could be
explained by two previously identified mechanisms: attenuation of motivational salience of
the CS and interoceptive drug state-mediated drug memory (Feng et al., 2012; Li et al.,
2007, 2009a, b; Mead and Li, 2010; Zhang et al., 2011). At the neuroreceptor level, previous
work has suggested that dopamine D2/3 and serotonin 5-HT2A/2C receptors systems may
play important roles in antipsychotic sensitization and tolerance (Li et al., 2012, 2010). In
the CAR test, we show that olanzapine sensitization may be mediated by D2 and 5-HT2A
blockade-initiated neuroplasticity (e.g. down-regulating 5-HT2A receptor), whereas
clozapine tolerance may be mediated by D2 blockade-initiated neuroplasticity (Atkins et al.,
1999; Kapur et al., 2003; Moran-Gates et al., 2006). In the PCP model, it has been shown
that acute atypical drugs such as clozapine and olanzapine inhibit PCP-induced
hyperlocomotion primarily due to their multiple actions on D2 and 5-HT2A receptors
(Gleason and Shannon, 1997; Maurel-Remy et al., 1995; Millan et al., 1999). 5-HT2A
receptors may be even more important than D2 receptors due to the fact that other 5-HT2A
antagonists such as LY53857, ritanserin, ketanserin, fananserin, and MDL 100, 907 are
more effective than dopamine antagonists in suppressing PCP-induced hyperlocomotion
(Gleason and Shannon, 1997; Millan et al., 1999); and repeated administration of clozapine
causes a down-regulation of 5-HT2A receptors in the prefrontal cortex (Doat-Meyerhoefer et
al., 2005). Because PCP also enhances serotonergic, dopaminergic and glutamatergic
neurotransmission in the nucleus accumbens and prefrontal cortex (Abekawa et al., 2007;
Maurel-Remy et al., 1995; Millan et al., 1999), we have proposed that antipsychotic
sensitization in the PCP-induced hyperlocomotion test is mediated by down-regulating 5-
HT2A receptors and concomitantly decreasing PCP-induced dopamine and 5-HT increases in
the prefrontal cortex (Sun et al., 2009).
In the case of asenapine, we would speculate that similar to olanzapine sensitization,
asenapine sensitization in both the CAR and PCP models may also be mediated by its
actions on D2 (up-regulation) and 5-HT2A receptor (down-regulation) systems. This
speculation is supported by the findings that asenapine has a relatively high occupancy of 5-
HT2A compared with the D2 receptor, a profile similar to that of olanzapine (Meltzer et al.,
2009); and chronic asenapine treatment increases D2 receptor and decreases 5-HT2A
receptor binding in the medial prefrontal cortex (Tarazi et al., 2008, 2010), an effect also
shared by olanzapine (Tarazi et al., 2001); and also by the findings that asenapine has a local
5-HT2A receptor antagonistic activity in the medial prefrontal cortex and can dose-
dependently increase extracellular dopamine release in this area (Franberg et al., 2012,
2008). Because chronic treatment of asenapine also alters other receptor systems, notably 5-
HT1A, D4, NMDA, and adrenergic α1 and α2 receptors (Choi et al., 2010; Franberg et al.,
2012; Shahid et al., 2009; Tarazi and Neill, 2012), their involvement in asenapine
sensitization also needs to be examined; and the two behavioral paradigms introduced in this
study provide a valid approach in addressing this issue.
One limitation of the present study is that the clozapine challenge test was always conducted
after the olanzapine test. There was a possibility that the clozapine’s effect on avoidance
response and PCP-induced hyperlocomotion had been altered by olanzapine exposure; thus,
it would be problematic if we only rely on the behavioral profile in the challenge tests to
make comparison between asenapine and clozapine. Another limitation is that we did not
directly examine the brain mechanisms of asenapine sensitization and did not examine
parameters (e.g. number of drug injections, interval between initial drug exposure and
challenge test, etc.) that influence the development and expression of asenapine
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sensitization. Future studies should examine these issues to enhance our understanding of
the repeated effects of asenapine.
In summary, asenapine is a new antipsychotic drug which shares a similar behavioral profile
with olanzapine but differs from clozapine on the basis of the findings that its repeated
treatment caused an olanzapine-like sensitization effect in both the CAR and PCP-induced
hyperlocomotion tests. Future work on the neurobiological mechanisms of asenapine
sensitization may further enhance our understanding of antipsychotic sensitization in general
and asenapine sensitization in particular. Such knowledge may also be useful for future drug
discovery.
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Fig. 1. A schematic illustration of the experimental procedure and groups in Experiment 1 (CAR
model)
ASE: asenapine; OLZ: olanzapine; CLZ: clozapine; VEH: vehicle.
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Fig. 2. A schematic illustration of the experimental procedure and groups in Experiment 2 (PCP
model)
ASE: asenapine; PCP: phencyclidine; OLZ: olanzapine; CLZ: clozapine; VEH: vehicle.
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Fig. 3. Repeated asenapine treatment increased avoidance response disruption but did not affect
22 kHz USV
Number of avoidance responses made by the rats from the three asenapine treatment groups
(ASE, 0.05, 0.10, and 2.0 mg/kg) and the vehicle group on the last training (pre-drug) day
and throughout the five drug test days are expressed as mean + SEM. **p < 0.001 relative to
the VEH group; ##p < 0.004 the ASE 0.10 and ASE 0.20 groups relative to the ASE 0.05
group.
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Fig. 4. Prior asenapine treatment increased sensitivity to asenapine re-exposure and olanzapine
exposure in the avoidance response
Number of avoidance responses in the asenapine (0.10 mg/kg) challenge test (A), olanzapine
(0.50 mg/kg) challenge test (B) and clozapine (2.50 mg/kg) challenge test (C) is expressed
as mean + SEM. *p < 0.05, **p < 0.01 relative to the VEH group; #p < 0.05 relative to the
ASE 0.05 group.
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Fig. 5. Repeated asenapine treatment increased inhibition of PCP-induced hyperlocomotion
throughout the 5 drug test days
(A) Locomotor activity was measured for 60 min after vehicle or PCP injection and
expressed as mean + SEM for each group. Asenapine (0.05, 0.10 and 0.20 mg/kg) was
injected 30 min before the vehicle or PCP injection. *p < 0.05 relative to the VEH + VEH
group, **p < 0.001 ASE 0.20 + PCP group (day 1) and VEH + PCP, ASE 0.05 + PCP and
ASE 0.10 + PCP group (all 5 days) relative to the VEH + VEH group; ##p < 0.01 relative to
the VEH + PCP group; &p < 0.05, &&p < 0.01 the 3 ASE group relative to each other. (B,
C, D, E, and F) Locomotor activity in 12 5-min blocks of individual group on day 1 and day
5. $p < 0.05, $$p < 0.001 day 5 relative to day 1.
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Fig. 6. Prior asenapine treatment increased the inhibition of PCP-induced hyperlocomotion upon
asenapine re-exposure and on olanzapine and clozapine treatment
(A) Locomotor activity was measured for 60 min after vehicle or PCP (3.20 mg/kg, sc)
injection and expressed as mean + SEM for each group. Asenapine (0.10 mg/kg, sc) was
injected 30 min before the vehicle or PCP injection. (B) Locomotor activity was measured
for 60 min after vehicle or PCP injection and expressed as mean + SEM for each group.
Olanzapine (0.50 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (C)
Locomotor activity was measured for 60 min after vehicle or PCP injection and expressed as
mean + SEM for each group. Clozapine (2.50 mg/kg, sc) was injected 30 min before the
vehicle or PCP injection. (n = 8/group). **p ≤ 0.001 relative to VEH + VEH-1 group; #p <
0.05, ##p ≤ 0.001 relative to VEH + VEH-2; &p < 0.05, &&p ≤ 0.004 relative to VEH +
PCP; $p < 0.05, $$p ≤ 0.009 relative to ASE 0.20 + PCP group.
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